Cargando…
Eukaryotic translation initiation factors as promising targets in cancer therapy
The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the pri...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640403/ https://www.ncbi.nlm.nih.gov/pubmed/33148274 http://dx.doi.org/10.1186/s12964-020-00607-9 |
_version_ | 1783605740802408448 |
---|---|
author | Hao, Peiqi Yu, Jiaojiao Ward, Richard Liu, Yin Hao, Qiao An, Su Xu, Tianrui |
author_facet | Hao, Peiqi Yu, Jiaojiao Ward, Richard Liu, Yin Hao, Qiao An, Su Xu, Tianrui |
author_sort | Hao, Peiqi |
collection | PubMed |
description | The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the primary targets of several signaling pathways to regulate gene expression. Mis-regulated mRNA expression is a common feature of tumorigenesis and the abnormal activity of eIF complexes triggered by upstream signaling pathways is detected in many tumors, leading to the selective translation of mRNA encoding proteins involved in tumorigenesis, metastasis, or resistance to anti-cancer drugs, and making eIFs a promising therapeutic target for various types of cancers. Here, we briefly outline our current understanding of the biology of eIFs, mainly focusing on the effects of several signaling pathways upon their functions and discuss their contributions to the initiation and progression of tumor growth. An overview of the progress in developing agents targeting the components of translation machinery for cancer treatment is also provided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-020-00607-9. |
format | Online Article Text |
id | pubmed-7640403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76404032020-11-04 Eukaryotic translation initiation factors as promising targets in cancer therapy Hao, Peiqi Yu, Jiaojiao Ward, Richard Liu, Yin Hao, Qiao An, Su Xu, Tianrui Cell Commun Signal Review The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for gene expression, and occurs principally at the initiation phase which is mainly regulated by eukaryotic initiation factors (eIFs). eIFs are fundamental for the translation of mRNA and as such act as the primary targets of several signaling pathways to regulate gene expression. Mis-regulated mRNA expression is a common feature of tumorigenesis and the abnormal activity of eIF complexes triggered by upstream signaling pathways is detected in many tumors, leading to the selective translation of mRNA encoding proteins involved in tumorigenesis, metastasis, or resistance to anti-cancer drugs, and making eIFs a promising therapeutic target for various types of cancers. Here, we briefly outline our current understanding of the biology of eIFs, mainly focusing on the effects of several signaling pathways upon their functions and discuss their contributions to the initiation and progression of tumor growth. An overview of the progress in developing agents targeting the components of translation machinery for cancer treatment is also provided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-020-00607-9. BioMed Central 2020-11-04 /pmc/articles/PMC7640403/ /pubmed/33148274 http://dx.doi.org/10.1186/s12964-020-00607-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Hao, Peiqi Yu, Jiaojiao Ward, Richard Liu, Yin Hao, Qiao An, Su Xu, Tianrui Eukaryotic translation initiation factors as promising targets in cancer therapy |
title | Eukaryotic translation initiation factors as promising targets in cancer therapy |
title_full | Eukaryotic translation initiation factors as promising targets in cancer therapy |
title_fullStr | Eukaryotic translation initiation factors as promising targets in cancer therapy |
title_full_unstemmed | Eukaryotic translation initiation factors as promising targets in cancer therapy |
title_short | Eukaryotic translation initiation factors as promising targets in cancer therapy |
title_sort | eukaryotic translation initiation factors as promising targets in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640403/ https://www.ncbi.nlm.nih.gov/pubmed/33148274 http://dx.doi.org/10.1186/s12964-020-00607-9 |
work_keys_str_mv | AT haopeiqi eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT yujiaojiao eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT wardrichard eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT liuyin eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT haoqiao eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT ansu eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy AT xutianrui eukaryotictranslationinitiationfactorsaspromisingtargetsincancertherapy |